Table 1 Linear regression and correlation analyses of proteins with differential abundance in the invasive tumor front and inner tumor with clinicopathological variables of the cases used for LMD and LC-MS/MS
From: Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer
Tumor area | Protein | Gene name | Uniprot ID | Abundance (ITF/Inner tumor ratio) | Clinicopathological data | Linear regression (P value) | Correlation coefficient (R) | R-squared |
|---|---|---|---|---|---|---|---|---|
Neoplastic islands | Actin-related protein 2 | ACTR2 | P61160 | −0.57 | Second primary tumor | 0.002 | −0.7 | 0.4 |
Neoplastic islands | Cystatin-B | CSTB | P04080 | −1.55 | Treatment | 0.0009 | 0.7 | 0.5 |
Neoplastic islands | Collagen alpha-2(I) chain | COL1A2 | P08123 | 1.07 | Treatment | 0.001 | 0.7 | 0.4 |
Neoplastic islands | Leukotriene A-4 hydrolase | LTA4H | P09960 | −0.83 | Second primary tumor | 0.001 | −0.7 | 0.4 |
Neoplastic islands | Phosphoglycerate kinase 1 | PGK1 | P00558 | −0.48 | Disease-free survival | 0.001 | — | 0.4 |
Neoplastic islands | Phosphoglycerate kinase 1 | PGK1 | P00558 | −0.48 | Second primary tumor | 0.001 | −0.7 | 0.4 |
Neoplastic islands | Protein NDRG1 | NDRG1 | Q92597 | −1.47 | Disease-free survival | 0.001 | — | 0.4 |
Neoplastic islands | Protein S100-A8 | S100A8 | P05109 | 2.11 | Second primary tumor | 0.0003 | −0.7 | 0.5 |
Neoplastic islands | Protein S100-A9 | S100A9 | P06702 | 2.35 | Second primary tumor | 0.0006 | −0.7 | 0.5 |
Tumor stroma | Collagen alpha-1(VI) chain | COL6A1 | P12109 | 0.534 | Lymph node status | 0.0006 | 0.7 | 0.5 |
Tumor stroma | Fascin | FSCN1 | Q16658 | −0.673 | Poorly differentiated tumor (WHO) | 2.34e-05 | 0.8 | 0.7 |
Tumor stroma | Integrin alpha-V | ITGAV | P06756 | −1.674 | Lymph node status | 0.0014 | 0.7 | 0.5 |
Tumor stroma | Myoglobin | MB | P02144 | 2.901 | Clinical stage | 0.0015 | 0.7 | 0.5 |
Tumor stroma | Thrombospondin-2 | THBS2 | P35442 | −0.712 | Lymph node recurrence | 0.0001 | 0.7 | 0.6 |
